Why the AFT Pharmaceuticals (ASX:AFP) share price is in focus

The AFT Pharmaceuticals (ASX: AFP) share price is one to watch today after the company signed a new US licensing deal with a major supplier.

| More on:
A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The AFT Pharmaceuticals Ltd (ASX: AFP) share price is one to watch this morning.

Shares in the Kiwi-Australian pharmaceuticals group could be on the move after the company announced a new licensing agreement in the United States.

Why is the AFT Pharmaceuticals share price in focus?

This morning, the company announced the signing of an exclusive license and distribution agreement with Hikma Pharmaceuticals USA ("Hikma"). The new deal is to commercialise Maxigesic IV in the United States with the major pharmaceuticals supplier.

Maxigesic IV is an intravenous, opioid free, postoperative pain relief medicine developed by AFT. Today's agreement represents the first out-license of the Maxigesic family of medicines in the US market.

That's an important milestone for the company and the AFT Pharmaceuticals share price is one to watch as a result. In today's release, AFT also said it was targeting the US market for the tablet and liquid forms of the medication in the longer term.

What are the terms?

Under the terms of the agreement, Hikma will have exclusive rights for the sales, marketing and distribution of Maxigesic IV in the US. AFT will receive upfront, regulatory and commercial milestone payments of up to US$18.8 million in return.

The milestone payments comprise US$7.5 million based on triggers leading up to and including registration and first commercial sale of the product. US$3.6 million of those will be earned once Food and Drug Administration (FDA) approval is received. The trans-Tasman pharma group will also receive a profit share from in market product sales.

That's potentially big news which puts the AFT Pharmaceuticals share price on watch this morning. Shares in the pharma group are down 28.0% in 2021 with a market capitalisation of $381.6 million prior to the open.

Foolish takeaway

Hikma is the third largest US supplier of generic injectable medicines by volume. AFT also said it is working to complete FDA approval for the tablet form of the medication.

Investors will be watching the AFT Pharmaceuticals share price ahead of its audited financial results in May.

Motley Fool contributor Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Two lab workers fist pump each other.
Healthcare Shares

Guess which ASX 200 healthcare stock is starting the week with a bang on big news!

What is getting investors excited today? Let's find out.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 small-cap ASX healthcare shares 'with strong prospects'

Fund manager IML discusses why these 3 ASX healthcare shares are likely to rise in value.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

2 All Ords ASX healthcare shares making BIG moves on quarterly updates

These two ASX healthcare companies are seeing heavy trading on Thursday.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

'Trading at a discount': Why now is the time to buy CSL shares

This investing expert says CSL shares now represent an appealing buying opportunity.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

Here's what could impact CSL shares from the biotech's AGM

The biotech giant's leadership had plenty to say.

Read more »

Man with a sleep apnoea mask on whilst sleeping.
Healthcare Shares

Why this fundie is backing ResMed shares in FY25

There's plenty more upside, this fund says.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Healthcare Shares

ResMed shares jump 8% on stellar start to FY25

This high-quality company continues to deliver the goods.

Read more »

Senior woman with caregiver in the garden
Healthcare Shares

A 'golden era' is coming for these ASX healthcare shares

Here's why Blackwattle Partners sees tailwinds ahead for one particular category of healthcare shares.

Read more »